What defines sustained biological remission in autoimmune hepatitis?

Sustained Biological Remission in Autoimmune Hepatitis

Sustained biological remission (also termed complete biochemical remission or CBR) requires normal serum aminotransferases (AST and ALT) AND normal IgG levels maintained for at least 2 years during treatment. 1, 2

Specific Biochemical Criteria

The most recent EASL 2025 guidelines define sustained CBR as requiring:

• Duration: At least 2 years of continuous normal values, with the most recent guidance suggesting treatment duration of at least 4 years total, with the last 2 years in sustained CBR 1
• ALT threshold: Deeply normal ALT (below half the upper limit of normal) provides better predictive value for sustained remission after treatment withdrawal 1, 2
• IgG threshold: Normal IgG levels, ideally <1,200 mg/dL 2

Important Nuances and Caveats

The Biochemical-Histological Disconnect

Biochemical remission does not guarantee histological remission, particularly in patients with cirrhosis:

• In non-cirrhotic AIH patients with normal ALT, 88% achieve histological remission 3
• In cirrhotic AIH patients with normal ALT, only 26% achieve histological remission, while 36% show moderate-to-high histological activity 3
• Overall, 46% of patients achieving biochemical remission still have persisting histological activity (Ishak HAI ≥4), which is associated with reduced fibrosis regression and excess mortality 4

Gradations Within "Normal"

Not all normal values predict the same outcomes:

• ALT <50% of upper limit normal combined with IgG <1,200 mg/dL identifies patients with better sustained remission rates after treatment withdrawal 2
• Complete biochemical remission (both ALT and IgG normalized) is a stronger predictor of histological remission and fibrosis regression than ALT normalization alone 5

Clinical Implications for Monitoring

Patients must be monitored indefinitely even after achieving sustained CBR, as:

• 50% of relapses occur within 3 months of treatment withdrawal 2
• 90% of relapses occur within 28 months, but late relapses can occur years later 2
• Monitoring should include aminotransferases and IgG at regular intervals of increasing length depending on test stability 2

Role of Liver Biopsy

The 2025 EASL guidelines suggest that liver biopsy before treatment withdrawal can be considered but is not mandatory in all adults 1. However:

• Histological remission (absence of inflammation) reduces relapse risk to 28% compared to higher rates with biochemical remission alone 2
• In children, pre-withdrawal liver biopsy remains strongly advised 2
• In cirrhotic patients, liver biopsy is particularly important since biochemical markers are unreliable indicators of histological activity 3

Common Pitfalls to Avoid

1. Don't equate biochemical remission with cure: Nearly half of patients have ongoing histological activity despite normal labs 4
2. Don't ignore IgG levels: Monitoring ALT alone is insufficient; IgG normalization is equally important 1, 2
3. Don't assume cirrhotic patients are in remission based on labs alone: These patients require more intensive monitoring, potentially including biopsy 3
4. Don't stop monitoring after treatment withdrawal: Relapse surveillance must continue indefinitely 2